Circulating tumor markers in gynecological tumors.
The correct use of tumor markers in patients with gynecological cancers can make an impact on management of the disease. Their value in screening for ovarian cancer cannot be recommended outside trials. Increased levels of various markers give prognostic information that could alter therapy for patients with early ovarian or cervical carcinoma. Their main value is in monitoring the response to therapy and confirming relapse, for which they may be superior to scans.
Center for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK.
G J
GJ
Rustin
D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D018450:Disease Progression; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000378:metabolism; D005260:Female; D005819:Genetic Markers; D005833:Genital Neoplasms, Female / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D009363:Neoplasm Proteins / Q000032:analysis*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism; D011379:Prognosis; D014327:Trophoblasts / Q000378:metabolism; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000378:metabolism; D014846:Vulvar Neoplasms / Q000175:diagnosis / Q000378:metabolism
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D005819:Genetic Markers; D009363:Neoplasm Proteins